Nightly external trigeminal nerve stimulation to reduce ADHD symptoms in children with autism
Official title: Phase IIa Clinical Trial of External Trigeminal Nerve Stimulation for Autistic Children With Attention Deficit/Hyperactivity Disorder
Run by University of California, San Francisco · NCT07214545 · Data updated 2026-11-12
This trial will test whether a small, nightly forehead patch that delivers external trigeminal nerve stimulation can reduce ADHD symptoms in children with autism.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 7 Years to 14 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | October 6, 2025 |
| Main results expected | September 2027 |
| Study ends | January 31, 2028 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07214545 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children with a clinician-confirmed DSM-5 diagnosis of autism, IQ above 70, a confirmed DSM-5 ADHD diagnosis with an ADHD-RS score over 24, stable medications for at least four weeks, and fluency in English for both child and caregiver.
✕Probably not a fit
Children with lower intellectual functioning (IQ ≤ 70), unstable major psychiatric conditions (for example current major depression, psychosis, or bipolar disorder), inability to tolerate or use the adhesive forehead device, or who cannot attend UCSF visits are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Children with clinician-confirmed autism and ADHD are randomly assigned to nightly active or sham external trigeminal nerve stimulation for about 8–12 weeks, with the option to try the active device later if they start on sham. Participation involves 4–5 in-person visits at UCSF plus four brief virtual check-ins, and nightly use of a small adhesive patch on the forehead while sleeping. Outcome measures include change in ADHD symptom scores, measures of core and associated autism features, cognitive testing, and tolerability/safety monitoring. The trial is designed as a randomized, blinded comparison of active versus sham stimulation to separate device effects from placebo and to gather short-term efficacy and safety data.
Why it matters
Potential benefit: If successful, this approach could provide a non-medication option that reduces ADHD symptoms and may improve some autism-related behaviors for some children.
How similar studies have gone: Earlier small trials of external trigeminal nerve stimulation have shown symptom improvements in pediatric ADHD, but evidence specifically in children with co-occurring autism is limited and still emerging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed clinician diagnosis of ASD according to DSM-5 criteria, corroborated by prior testing (or obtained in study screening) with the Autism Diagnostic Observation Schedule (ADOS) with or without the Autism Diagnostic Interview-Revised (ADI-R) * IQ \> 70 as corroborated by prior testing (or obtained in study screening) with the Wechsler Abbreviated Scale of Intelligence Scale (WASI) * Confirmed diagnosis of ADHD according to DSM-5 criteria with minimum ADHD-RS score of \> 24 * Stable on current medications for a minimum of 4 weeks before baseline * Ability to complete protocol testing * Both the child participant and their primary caregiver must be fluent in English (speaking, reading, and understanding), as the questionnaires and assessment tools used in this study have been validated only in English. Exclusion Criteria: * Current major depression, history of psychosis, bipolar disorder, elevated risk of self-harm * History of moderate to severe coarse brain injury * Active medical illness expected to interfere with study assessments * Presence of implanted stimulator (e.g., vagal nerve stimulator) * Active dermatologic condition likely to interfere with eTNS electrode wearability * Sleep disorder likely to interfere with nightly eTNS in the opinion of the study physician * Inability to communicate discomfort or pain * Current and anticipated continued use of antipsychotic or stimulant medication
Where it's running
-
UCSF Nancy Friend Pritzker Psychiatry Building
San Francisco, California, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pai.ACT: AI-powered chatbot-assisted ACT for parents of children with neurodevelopmental disorders
This trial tests a chatbot-guided ACT program for Cantonese-speaking parents of young children with neurodevelopmental disorders to see if it helps reduce parenting stress and improves family well-being.
-
Clown therapy to help kids with autism sit for dental visits
This study tests whether clown therapy can help children with autism sit through a dental examination more easily than conventional familiarization methods.
-
French Minds: a French, Multimodal Cohort Study of Severe Psychiatric Disorders and Healthy Controls
This study tests whether people with mood, psychotic, or autism disorders can be grouped into more similar subtypes based on social withdrawal and anhedonia, across ages 15 to 60.
-
Cardiorespiratory and muscular fitness in children with obesity and autism
This study tests whether cardiorespiratory fitness and handgrip strength differ between children with obesity who have autism and those who do not, and how these fitness measures relate to body size, composition, and cardiometabolic health.
-
Transitional Intervention for Hyperacusis in Autism
Aiming to see if a transitional sound-therapy approach can help adults with autism tolerate everyday sounds better and reduce loudness-related distress.
-
Museum visits to support social and emotional well‑being in autistic adults
This study tests whether visiting the National Taiwan Museum can help improve social participation and well-being for autistic adults aged 18–50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.